IHME model predicts global deaths will peak in December, with fatalities expected to reach as high as 30,000 a day.
- India’s caseload topped four million, while South Korea posted its lowest daily tally in three weeks. Police in Australia’s Victoria state meanwhile braced for anti-lockdown protests, arresting at least four people for incitement.
- Iraq’s health ministry warned hospitals may “lose control” in the coming days after the country recorded its highest single-day rise in coronavirus cases since the start of the pandemic.
- The World Health Organization (WHO) does not expect widespread vaccinations against COVID-19 until the middle of next year, a spokeswoman said, stressing the importance of rigorous checks on their effectiveness and safety.
- More than 26.5 million people around the world have been diagnosed with the coronavirus, and more than 872,000 have died, according to Johns Hopkins University. More than 17.6 million people have recovered.
Here are the latest updates:
Saturday, September 5
India crosses four million virus cases with record surge
India’s total coronavirus cases surged beyond four million with a record rise, making it the third country in the world to surpass that mark, following the United States and Brazil.
India added 86,432 cases of the new virus, a global daily record, according to data from the federal health ministry.
Infections rose across the country, including in the capital New Delhi and the large states of Maharashtra and Karnataka. The number of deaths in India from the COVID-19 rose by more than 1,000 to 69,561 on Saturday.
The number of deaths in India from the COVID-19 rose by more than 1,000 to 69,561 [AP]
Brazil’s Tecpar to test Russian COVID-19 vaccine in early 2021
The technology institute for the Brazilian state of Paraná, which has signed an agreement to produce Russia’s Sputnik V coronavirus vaccine, said it plans to conduct phase III trials on 10,000 volunteers in Brazil at the start of next year.
Jorge Callado, head of Paraná’s Technology Institute, known as Tecpar, said approval for the trial will be requested of Brazil’s health regulator ANVISA by the end of this month. Doses will be imported for the tests and Tecpar plans to produce the vaccine for Brazil’s market in the second half of 2021, he said.